Donut Hole
Donut Hole refers to a prescription coverage gap found in Medicare (Part D) drug plans.
♦ Since 2025, the Donut Hole is gone. Not filled in with jelly. Just gone. This is the result of the Inflation Reduction Act of 2022 (IRA), signed on August 16, 2022 by President Biden.
♦ Once you hit the out-of-pocket maximum ($2,400 in 2027), you have exactly zero more costs ($0 copays) for the rest of the year.
The Inflation Reduction Act of 2022 includes several provisions to lower prescription drug costs for people with Medicare and reduce drug spending by the federal government.
• This legislation passed Congress on a party-line vote, with no Republican support, though its drug price provisions were popular with the public. It helps address some of the high cost of rising drug prices.
The CBO estimates that the drug pricing provisions in the law will reduce the federal deficit by $237 billion over 10 years (2022-2031).
• President Donald Trump's current policy agenda for Medicare emphasizes deregulation, market competition and reducing federal spending. Many critics and regional leaders warn there will likely be an increase in plan premiums for millions of seniors.
The administration says Medicare can now negotiate "most-favored-nation" pricing deals directly with pharmaceutical manufacturers. This plays well on TV, but Medicare itself doesn't use "most-favored-nation" (MFN) math for its standard drug price negotiations.
• Under the ongoing Medicare Drug Price Negotiation Program established by Congress, the Centers for Medicare & Medicaid Services (CMS) works directly with manufacturers to set a "Maximum Fair Price" (MFP) based on domestic criteria like research costs, production costs and patent life, not by pegging prices to what foreign countries pay.
Signed into law through the budget reconciliation process, Trump's One Big Beautiful Bill Act restricts eligibility.
• The law eliminates Medicare eligibility for specific non-citizen groups, including refugees, asylum seekers and individuals holding Temporary Protected Status (TPS).
Drug companies have been pushing hard to reverse many of the IRA's provisions that cut into their profits.
In the November 2026 midterm elections, Democrats were projected to win control of both the House and the Senate starting in January 2027. That makes a rollback of the IRA's drug pricing rules much less likely, at least for now.
We'll have to wait and see how this plays out. But as a rule, once something is given to people and they like it (lower drug costs), it's difficult to take it away. Remember how repealing the ACA went last time.
Prescription deductible to increase
In 2027, the maximum prescription deductible for Medicare (Part D) will be $700.
This means you'll need to pay the first $700 of your prescription drug costs before your Medicare drug plan starts covering a portion.
There are a variety of Advantage plans, but most will push their deductible up to the max and tinker with the generic drugs.
♦ Some plans will reclassify more expensive generic drugs as tier 3 drugs so they fall under the deductible. It's critical to review your plan's prescription drug list every year during open enrollment.
Most plans apply the deductible to brand drugs and some expensive generics. If you only take lower-cost generics, you may not be affected by this increase in the prescription deductible.
Catastrophic coverage
Total Medicare Part D gross prescription drug spending has reached about $276 billion a year. Most of that growth has been in the catastrophic phase of coverage, largely driven by the prices of specialty drugs.
♦ The catastrophic coverage phase still exists, but the rules have changed completely, so you no longer pay anything.
Today, the catastrophic phase works as a true, hard out-of-pocket maximum.
♦ Because the out-of-pocket maximum adjusts every year, the threshold to trigger catastrophic coverage will increase to $2,400 starting January 1, 2027.
Out-of-pocket cap
Adding an out-of-pocket cap to Part D had been proposed by policymakers on both sides of the aisle.
The Inflation Reduction Act of 2022 (IRA), signed on August 16, 2022 by President Biden, set an out-of-pocket cap. It started in 2025.
• In 2024, it eliminated the 5% copays in the catastrophic coverage level.
This wasn't a big change, but it lowered many people's total out-of-pocket costs considerably.
The biggest change took effect in 2025.
♦ Starting in 2025, there's what's called a "hard cap" on out-of-pocket spending, set at $2,000.
This "hard cap" isn't so hard, though. Going forward, the limit is allowed to increase based on future increases in Part D costs.
Allowing the "hard cap" to increase year after year is a big disappointment, especially for seniors living on Social Security and its limited increases.
Kaiser Family Foundation estimated that 1.4 million Part D enrollees had annual out-of-pocket costs for their medications above $2,000 in 2020, averaging $3,335 per person. This includes 1.3 million people who had spending above the catastrophic threshold.
If the $2,000 cap had been in place in 2020, those Part D enrollees would have saved $1,355 on average.
♦ The IRA also gives the federal government the right to negotiate the prices of a few expensive drugs each year. Negotiated prices started in 2026 for Part D drugs and will start in 2028 for Part B drugs.
The IRA limits insulin copays to $35 a month for Medicare Part D beneficiaries, starting in 2023. Senate Republicans blocked a broader version that would have included people with diabetes who have private insurance. So for now, this $35 copay limit applies only to people with Medicare.
• Some in the GOP have threatened to throw a monkey wrench into the works. Some believe drug companies shouldn't have to negotiate prices with the federal government.
The IRA is estimated to reduce the federal deficit by $237 billion over 10 years.
The IRA also limits growth in the national "base" Part D premium to no more than 6% a year from 2024 through 2029. That's a benchmark, not a cap on your plan's premium. Individual plan premiums can still rise more.
No cap for Part B drugs
Capping Part D drugs doesn't cap spending on Part B drugs. These are expensive drugs given in a doctor's office, usually by injection or infusion. These drugs are subject to 20% coinsurance with no cap.
Some Medicare beneficiaries have retiree benefits or Medigap coverage to help pay their 20% share. Older KFF estimates found several million beneficiaries have no supplemental coverage at all.
Another 35 million are enrolled in Medicare Advantage plans, where they typically face 20% coinsurance up to their plan's out-of-pocket maximum. That maximum was limited to $9,350 in 2025. Most Medicare Advantage plans set their limits close to the maximum allowed.
And once again, this limit isn't fixed. It's raised year after year.
♦ Part B drug costs can easily become excessive. For example, the Alzheimer's drug Leqembi lists at about $26,500 a year. A 20% cost-sharing responsibility would be more than $5,000 a year.
Advocates argue that it's Part B drugs that need immediate relief.
In October 2019, President Trump kicked the hornet's nest by proposing to tie some Medicare Part B drug prices to lower prices in other countries. He was immediately attacked by conservative groups and Big Pharma. It never went anywhere.
♦ President Trump is still pursuing international price benchmarking, and the effort has gone beyond a mere proposal.
Under his current legislative and regulatory frameworks, the administration has doubled down on what it calls the "Most-Favored-Nation" (MFN) drug pricing model, to push U.S. drug prices toward the lower prices paid in other wealthy nations.
Rather than abandoning the 2019 "hornet's nest" proposal, the administration has taken a two-part approach to lock this framework into the health care system. It calls them the GLOBE Model and the GUARD Model.
Both models are very complicated and far beyond the scope of this article. Drug companies and their lobbyists are actively resisting them.
Several pharmaceutical companies have signed voluntary agreements, but then turned around and raised prices on many brand-name drugs. So, what's up?
Donut Hole - Gone
The donut hole is explained below for reference and a bit of history. And so people don't forget how things used to be.
Medicare plans with prescription drug coverage (Part D) used to have a coverage gap called a "Donut Hole." This was true for Medicare Advantage plans too.
♦ What this meant is that after you and your drug plan had spent a certain amount of money on covered drugs (the initial period), you had to pay all costs out-of-pocket for your prescriptions up to the Donut Hole limit.
→ "All" might not be the best way of describing what you actually paid while in the Donut Hole. You paid no more than 25% of the price for brand-name and generic drugs. Brand-name drugs were the big-ticket items.
Once you spent up to the yearly limit, your coverage gap ended and Catastrophic coverage kicked in to help pay for covered drugs until the end of the year.
♦ Starting in 2025, there's what's called a "hard cap" on out-of-pocket spending, set at $2,000. It increases some each year. It will be $2,400 for 2027.
Historical Info
♦ For 2024, the Donut Hole started at $5,030 and ended at $8,000. A $2,970-wide hole.
♦ For 2023, the Donut Hole started at $4,660 and ended at $7,400. A $2,740-wide hole.
♦ For 2022, the Donut Hole started at $4,430 and ended at $7,050. A $2,620-wide hole.
— In 2024, the hole widened another $230 but shifted $370, so you might have fallen into the hole a little later. But you had to pay more to get out of the hole.
♦ In 2023, the hole widened $120 but shifted $230.
• In 2022, the hole widened $200 but shifted $200.
The news was always about the closing of the Donut Hole. This was a little misleading, because the hole was still there. It was also getting wider every year.
♦ The Donut Hole was never going to be eliminated from your Medicare Part D prescription drug coverage unless a new law was written to make it happen. That law was the Inflation Reduction Act of 2022 (IRA).
Many people used the word "eliminated," but what was actually happening was that the gap between what counted toward getting out of the Donut Hole was shrinking.
Since 2020, both brand-name and generic drugs cost a fixed 25% of retail while you were in the Donut Hole.
Compare that to 2019, when brand-name drugs cost a fixed 25% of retail and generics cost 37%.
% Paid while in Donut Hole
| Year | Brand | Generic |
|---|---|---|
| 2018 | 35% | 44% |
| 2019 | 25% | 37% |
| 2020 | 25% | 25% |
| 2021 | 25% | 25% |
| 2022 | 25% | 25% |
Both classes of drugs counted toward getting out of the Donut Hole and into the next stage of drug coverage, called Catastrophic Coverage.
After your costs reached the Donut Hole level, you paid no more than 25% for most brand-name drugs and biological drugs bought while you were in the coverage gap. The savings came from additional manufacturer discounts (70%) and the federal government paying more.
♦ In 2024, you stayed in this gap (Donut Hole) until total costs reached $8,000.
It's a bit confusing, but 95% of the cost of brand drugs counted toward getting out of the gap. What you paid (25%) plus the manufacturer discount (70%) was added to your total as if it were an expense, which helped you get out of the coverage gap faster.
♦ Generics were treated differently. During the coverage gap, you paid 25% of the price for generic drugs.
For generic drugs, only the amount you paid (25%) counted toward getting you out of the coverage gap.
Deductibles counted, but drug plan premiums didn't. 75% of any pharmacy dispensing fees paid by the plan also didn't count.
♦ CMS has been allowing the deductible limit to drift up every year, and this is continuing. In 2027 it will reach $700 for Part D prescriptions.
What this means is that Part D plans and Advantage plans have the go-ahead to raise their prescription deductible. Most will jack the deductible up close to the maximum, and most will continue to apply the deductible to higher-tier drugs, like brand drugs.
• A few plans are changing their drug formulary to reclassify more expensive generic drugs as tier 3 drugs, so they fall under the deductible. It's critical to review your plan's formulary for next year.
♦ The cumulative savings passed $26.8 billion by the time the Affordable Care Act's (ACA) gradual closing of the "donut hole" was fully completed in 2020.
♦ End result: people using generic drugs saved some money while in the Donut Hole. However, with the Donut Hole widening, someone using a lot of prescriptions was likely to pay considerably more than in 2023. It was like one of those "dog chasing its tail" moments.
→ Some Medicare drug plans were already including coverage in the gap. People with those plans ended up paying less.
How we finally got there
In 2022, Senate Republicans proposed a $3,100 limit and House Democrats pushed a $2,000 limit. Both plans would have required manufacturers to kick in a greater percentage. At the time, manufacturers kicked in 0% in the catastrophic phase.
Under the Senate plan they would have been asked for 14%, and under the House plan it would have been 30%.
Both proposals pushed the plan sponsors (insurance companies) to cover a much higher percentage. The reasoning was that insurance companies would likely negotiate more aggressively with manufacturers for better prices.
Beneficiaries would benefit greatly, and the federal government would also cut its spending in the catastrophic phase from the then-current 80% level down to 20% for brand drugs and 40% for generic drugs.
• Insurance companies weren't happy, and big bad pharma cried up a storm. They've since turned to promoting conservative candidates willing to run ads claiming Medicare recipients have lost something.
Now, with a hard cap in place, things are more predictable. Still…
• It's best to review your coverage during open enrollment, October 15 to December 7.